170 related articles for article (PubMed ID: 25591504)
1. Shorter treatments for hepatitis C: another step forward?
Foster GR
Lancet; 2015 Mar; 385(9973):1054-5. PubMed ID: 25591504
[No Abstract] [Full Text] [Related]
2. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
Kohli A; Osinusi A; Sims Z; Nelson A; Meissner EG; Barrett LL; Bon D; Marti MM; Silk R; Kotb C; Gross C; Jolley TA; Sidharthan S; Petersen T; Townsend K; Egerson D; Kapoor R; Spurlin E; Sneller M; Proschan M; Herrmann E; Kwan R; Teferi G; Talwani R; Diaz G; Kleiner DE; Wood BJ; Chavez J; Abbott S; Symonds WT; Subramanian GM; Pang PS; McHutchison J; Polis MA; Fauci AS; Masur H; Kottilil S
Lancet; 2015 Mar; 385(9973):1107-13. PubMed ID: 25591505
[TBL] [Abstract][Full Text] [Related]
3. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
Townsend K; Meissner EG; Sidharthan S; Sampson M; Remaley AT; Tang L; Kohli A; Osinusi A; Masur H; Kottilil S
AIDS Res Hum Retroviruses; 2016 May; 32(5):456-62. PubMed ID: 26559180
[TBL] [Abstract][Full Text] [Related]
4. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
5. Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.
Dvory-Sobol H; Voitenleitner C; Mabery E; Skurnac T; Lawitz EJ; McHutchison J; Svarovskaia ES; Delaney W; Miller MD; Mo H
Antimicrob Agents Chemother; 2014 Nov; 58(11):6599-606. PubMed ID: 25155588
[TBL] [Abstract][Full Text] [Related]
6. Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
Øvrehus ALH; Krarup H; Birkemose I; Holm DK; Mössner B; Ernst A; Christensen PB
J Hepatol; 2018 Apr; 68(4):840-842. PubMed ID: 29223370
[No Abstract] [Full Text] [Related]
7. Therapy for hepatitis C--the costs of success.
Hoofnagle JH; Sherker AH
N Engl J Med; 2014 Apr; 370(16):1552-3. PubMed ID: 24725236
[No Abstract] [Full Text] [Related]
8. Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults.
Barocas JA; Beiser M; León C; Gaeta JM; O'Connell JJ; Linas BP
JAMA Intern Med; 2017 Jun; 177(6):880-882. PubMed ID: 28395004
[No Abstract] [Full Text] [Related]
9. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
Kowdley KV; Gordon SC; Reddy KR; Rossaro L; Bernstein DE; Lawitz E; Shiffman ML; Schiff E; Ghalib R; Ryan M; Rustgi V; Chojkier M; Herring R; Di Bisceglie AM; Pockros PJ; Subramanian GM; An D; Svarovskaia E; Hyland RH; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Pound D; Fried MW;
N Engl J Med; 2014 May; 370(20):1879-88. PubMed ID: 24720702
[TBL] [Abstract][Full Text] [Related]
10. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Afdhal N; Zeuzem S; Kwo P; Chojkier M; Gitlin N; Puoti M; Romero-Gomez M; Zarski JP; Agarwal K; Buggisch P; Foster GR; Bräu N; Buti M; Jacobson IM; Subramanian GM; Ding X; Mo H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Mangia A; Marcellin P;
N Engl J Med; 2014 May; 370(20):1889-98. PubMed ID: 24725239
[TBL] [Abstract][Full Text] [Related]
11. The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
Nguyen THT; Guedj J; Uprichard SL; Kohli A; Kottilil S; Perelson AS
Sci Rep; 2017 Aug; 7(1):10233. PubMed ID: 28860456
[TBL] [Abstract][Full Text] [Related]
12. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
13. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
[No Abstract] [Full Text] [Related]
14. Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection.
Graf Einsiedel H; Christiansen H; Wiegand J
Pediatr Infect Dis J; 2016 Dec; 35(12):1373. PubMed ID: 27832030
[No Abstract] [Full Text] [Related]
15. Hepatitis C and HIV co-infection: closing the gaps.
Graham CS
JAMA; 2015 Mar 24-31; 313(12):1217-8. PubMed ID: 25705993
[No Abstract] [Full Text] [Related]
16. Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment.
Gentile I; Borgia G
Evid Based Med; 2014 Dec; 19(6):223-4. PubMed ID: 25028605
[No Abstract] [Full Text] [Related]
17. [Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment].
Kwon JH
Korean J Gastroenterol; 2015 Aug; 66(2):131-3. PubMed ID: 26513826
[No Abstract] [Full Text] [Related]
18. Viral hepatitis: new hepatitis C therapies-a medical pick and mix.
Ray K
Nat Rev Gastroenterol Hepatol; 2014 Jun; 11(6):329. PubMed ID: 24776807
[No Abstract] [Full Text] [Related]
19. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
[TBL] [Abstract][Full Text] [Related]
20. PHOTON-2: hope for patients with HIV and HCV co-infection?
Naggie S; Kim AY
Lancet; 2015 Mar; 385(9973):1052-4. PubMed ID: 25659286
[No Abstract] [Full Text] [Related]
[Next] [New Search]
